Erythropoeitin is the most important factor in the regulation of erythropoeisis. This study aimed to evaluate the efficacy of rhuESF for patients undergoing plastic surgical procedures during which notable blood loss is expected (reduction mammoplasty in cases of macromastia and abdominoplasty obese patients) to improve the full blood count and reduce the need for transfusion. The levels of hemoglobin were significantly greater for patients pretreated with erythropoeitin and iron than for the control group.
The use of recombinant human erythropoietin stimulating factor in plastic surgery / Ferraro, G.; Corcione, A.; Nicoletti, G. F.; Brongo, S.; Ciccarelli, F.; D'Andrea, Francesco. - In: AESTHETIC PLASTIC SURGERY. - ISSN 0364-216X. - 28(3):(2004), pp. 174-176. [10.1007/s00266-003-3070-6]
The use of recombinant human erythropoietin stimulating factor in plastic surgery
D'ANDREA, FRANCESCO
2004
Abstract
Erythropoeitin is the most important factor in the regulation of erythropoeisis. This study aimed to evaluate the efficacy of rhuESF for patients undergoing plastic surgical procedures during which notable blood loss is expected (reduction mammoplasty in cases of macromastia and abdominoplasty obese patients) to improve the full blood count and reduce the need for transfusion. The levels of hemoglobin were significantly greater for patients pretreated with erythropoeitin and iron than for the control group.| File | Dimensione | Formato | |
|---|---|---|---|
|
brongo.pdf
accesso aperto
Licenza:
Accesso privato/ristretto
Dimensione
80 kB
Formato
Adobe PDF
|
80 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
